Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults

Launched by JUST-EVOTEC BIOLOGICS · Apr 16, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new drug called JST-010 to see if it is safe for healthy adults aged 18 to 55. The main goal is to find out if a single injection of this drug can prevent pneumonic plague, a serious illness. Researchers will compare the effects of JST-010 with a placebo (a treatment with no active ingredients) to understand its safety and how it behaves in the body over time. Participants will spend the first three days in the clinic and will have several follow-up visits over one year for health checks and tests.

To join this study, participants need to be healthy adults within the specified age range, have a body mass index (BMI) between 18 and 32, and must not be pregnant or breastfeeding. They should also be in good health based on medical history and tests. However, certain conditions like recent illnesses, prior treatments for the plague, or specific medical conditions may exclude someone from participating. This study is not yet recruiting, but it aims to gather important information about JST-010 that could help in preventing serious infections in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy men or women 18 to 55 years of age
• • 2. BMI between 18 and 32 kg/m2
• • 3. Negative serum pregnancy test
• • 4. Use of highly effective birth control method(s) for a minimum of 60 days prior to consent and is willing to continue use for at least 12 months, or abstinence
• • 5. In good general health as determined by medical history, exams and tests
• Exclusion Criteria:
• • 1. Acute illness or fever (≥100.4°F) within 7 days prior to dosing
• • 2. Any history of receiving treatment, vaccine, or monoclonal antibodies (mAbs) against the Yersinia pestis bacterium
• • 3. Receipt of any vaccine within 30 days prior to Screening, planned receipt of any vaccine prior to Day 1, or planned receipt of any vaccines before 45 days post-injection.
• • 4. Any medical condition for which IM injections would be contraindicated in the opinion of the investigator (eg, bleeding disorders, anticoagulant therapy, and severe thrombocytopenia)
• • 5. History of congenital or acquired immunodeficiency syndrome
• • 6. Prior solid organ or bone marrow transplant
• • 7. Use of systemic steroids, immunosuppressive agents, anticoagulants, or antiarrhythmics within 1 year prior. A single short course (ie, less than 14 days) is allowed provided it is concluded more than 6 months prior to Screening
• • 8. Upper arm is with insufficient muscular tissue for IM injections or is obscured by tattoos or rash that may preclude accurate assessment of injection site reactions
• • 9. Use of any medications started within 30 days prior to Day -1, including prescription medications, nutritional supplements, and over-the-counter medications
• • Vitamin supplements are allowed
• • Recommended doses of acetaminophen are allowed, except for 24 hours prior to dosing
• • Recommended doses of non-steroidal anti-inflammatory drugs (NSAIDs) (eg, aspirin, ibuprofen) are also allowed, except for 7 days prior to dosing
• • 10. Positive human immunodeficiency virus (HIV-1/-2) antibody result by history or at Screening
• • 11. Positive hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C antibody
• • 12. Positive urine drug test or cotinine (indicating active current smoking) at Screening or Day -1, positive alcohol breath test at Screening or on Day -1, or suspected/known drug abuse and/or alcohol use disorder
• • 13. Smoking or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 3 months before study drug dosing
• • 14. Dosing in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer) of receiving the investigational drug prior to Screening
• • 15. Progressive, unstable, or uncontrolled medical conditions that have required medical attention or changes to medication for medical reasons within 90 days prior to consent
• • 16. History of allergic reactions or hypersensitivity reactions to other therapeutic antibodies or immunoglobulins
• • 17. Receipt of any mAbs in the 12 months prior to Screening
• • 18. High blood pressure
• • 19. History of hyperprolinemia
• • 20. Women who are either pregnant or breast-feeding
• • 21. Vulnerable individuals (eg, military recruits, persons in compulsory detention, those with limited legal capacity)
• • 22. Receipt of immunoglobulins or any blood products within 90 days prior to consent or planned receipt during the study period
• • 23. Donation or loss of \>500 mL of blood within 30 days or plasma within 7 days of Day 1; any planned donation of blood or plasma during the study period
• • 24. History of any malignant neoplasm within the last 5 years, with the exception of adequately treated localized or in situ non-melanoma carcinoma of the skin or the cervix
• • 25. Strenuous activity or contact sports within 48 hours before study drug dosing and through Day 8
• • 26. History of relevant drug and/or food allergies